晚期前列腺癌-话题@MedSci

#晚期前列腺癌#

44篇内容 | 1158人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1412802, encodeId=9eac141280264, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=BMC Urol：晚期前列腺癌患者服用阿帕鲁胺后出现皮疹，需要特殊处理吗？, objectType=article, longId=215377, objectId=ff6f2153e7d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff6f2153e7d8, replyNumber=0, likeNumber=39, createdTime=2021-08-07, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff6f2153e7d8, moduleTitle=BMC Urol：晚期前列腺癌患者服用阿帕鲁胺后出现皮疹，需要特殊处理吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff6f2153e7d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412801, encodeId=b87f1412801d8, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=European Urology：热门靶点CD38在晚期前列腺癌中的作用, objectType=article, longId=212625, objectId=c9f821262544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f821262544, replyNumber=0, likeNumber=44, createdTime=2021-06-13, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f821262544, moduleTitle=European Urology：热门靶点CD38在晚期前列腺癌中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9f821262544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412800, encodeId=eeed14128009d, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=Clin Cancer Res：对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制 , objectType=article, longId=207722, objectId=7efa20e722e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7efa20e722e0, replyNumber=0, likeNumber=41, createdTime=2021-03-01, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7efa20e722e0, moduleTitle=Clin Cancer Res：对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7efa20e722e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412799, encodeId=45631412e9995, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=J Clin Oncol：全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后, objectType=article, longId=206566, objectId=c971206566db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c971206566db, replyNumber=0, likeNumber=36, createdTime=2021-02-03, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c971206566db, moduleTitle=J Clin Oncol：全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c971206566db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412798, encodeId=6fc51412e984c, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=FDA批准口服GnRH受体拮抗剂Orgovyx治疗晚期前列腺癌, objectType=article, longId=204709, objectId=0a77204e09af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a77204e09af, replyNumber=0, likeNumber=34, createdTime=2020-12-22, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a77204e09af, moduleTitle=FDA批准口服GnRH受体拮抗剂Orgovyx治疗晚期前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a77204e09af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412797, encodeId=b5ff1412e9751, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=Eur Urol：ATM缺失的晚期前列腺癌：PARP和ATR抑制剂, objectType=article, longId=204467, objectId=de6a20446ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de6a20446ede, replyNumber=0, likeNumber=36, createdTime=2020-12-15, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de6a20446ede, moduleTitle=Eur Urol：ATM缺失的晚期前列腺癌：PARP和ATR抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de6a20446ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412796, encodeId=6f271412e9603, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月, objectType=article, longId=202159, objectId=6ecb20215929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ecb20215929, replyNumber=0, likeNumber=36, createdTime=2020-10-17, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ecb20215929, moduleTitle=真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ecb20215929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412795, encodeId=9dfb1412e9573, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=Brit J Cancer：晚期前列腺癌中富集的BCAS2蛋白能够与NBS1互作增强DNA双链断裂修复, objectType=article, longId=201776, objectId=46ed201e76a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ed201e76a5, replyNumber=0, likeNumber=38, createdTime=2020-10-08, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ed201e76a5, moduleTitle=Brit J Cancer：晚期前列腺癌中富集的BCAS2蛋白能够与NBS1互作增强DNA双链断裂修复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ed201e76a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412794, encodeId=1ed71412e9445, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=Communications Biology：晚期前列腺癌帐长非编码RNAs与雄激素受体剪接因子相关 , objectType=article, longId=199159, objectId=d98c19915921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98c19915921, replyNumber=0, likeNumber=35, createdTime=2020-08-12, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98c19915921, moduleTitle=Communications Biology：晚期前列腺癌帐长非编码RNAs与雄激素受体剪接因子相关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d98c19915921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412793, encodeId=0c1e1412e93e7, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=Nat Genet：晚期前列腺癌的DNA甲基化情况, objectType=article, longId=198658, objectId=613c1986585a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=613c1986585a, replyNumber=0, likeNumber=37, createdTime=2020-08-05, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=613c1986585a, moduleTitle=Nat Genet：晚期前列腺癌的DNA甲基化情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=613c1986585a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412792, encodeId=44681412e92d0, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=J Urol：GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率, objectType=article, longId=197429, objectId=877719e4295d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=877719e4295d, replyNumber=0, likeNumber=32, createdTime=2020-07-14, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=877719e4295d, moduleTitle=J Urol：GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=877719e4295d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412791, encodeId=827a1412e9127, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=NEJM：口服Relugolix治疗晚期前列腺癌, objectType=article, longId=195325, objectId=cf7a19532502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf7a19532502, replyNumber=0, likeNumber=32, createdTime=2020-06-06, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf7a19532502, moduleTitle=NEJM：口服Relugolix治疗晚期前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf7a19532502)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412790, encodeId=489d1412e905a, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验, objectType=article, longId=189089, objectId=994d1890897b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=994d1890897b, replyNumber=0, likeNumber=49, createdTime=2020-03-03, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=994d1890897b, moduleTitle=美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=994d1890897b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412789, encodeId=d05f1412e8916, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=2019 APCCC报告：晚期前列腺癌患者的管理, objectType=article, longId=188371, objectId=ed211883e1e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed211883e1e7, replyNumber=0, likeNumber=34, createdTime=2020-02-20, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed211883e1e7, moduleTitle=2019 APCCC报告：晚期前列腺癌患者的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed211883e1e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412788, encodeId=84bd1412e884f, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=叶定伟：晚期前列腺癌治疗进展盘点, objectType=article, longId=185733, objectId=fcc8185e33d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcc8185e33d4, replyNumber=0, likeNumber=43, createdTime=2020-01-07, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcc8185e33d4, moduleTitle=叶定伟：晚期前列腺癌治疗进展盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcc8185e33d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412787, encodeId=3cd31412e87b5, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%, objectType=article, longId=184163, objectId=972b1841632b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=972b1841632b, replyNumber=0, likeNumber=46, createdTime=2019-12-06, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=972b1841632b, moduleTitle=PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=972b1841632b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412786, encodeId=f3db1412e86ba, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, objectType=article, longId=184023, objectId=8e3e1840235e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3e1840235e, replyNumber=0, likeNumber=34, createdTime=2019-12-04, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3e1840235e, moduleTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3e1840235e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412785, encodeId=d3a81412e85c7, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=晚期前列腺癌新药研发竞争格局, objectType=article, longId=181778, objectId=20e1181e7823, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e1181e7823, replyNumber=0, likeNumber=41, createdTime=2019-10-24, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e1181e7823, moduleTitle=晚期前列腺癌新药研发竞争格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e1181e7823)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412784, encodeId=4cff1412e8424, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=新型晚期前列腺癌靶向诊疗技术在英国首次上市, objectType=article, longId=167675, objectId=2de616e6752c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de616e6752c, replyNumber=0, likeNumber=38, createdTime=2019-06-06, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de616e6752c, moduleTitle=新型晚期前列腺癌靶向诊疗技术在英国首次上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2de616e6752c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412783, encodeId=72d61412e8317, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, objectTitle=Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体, objectType=article, longId=158502, objectId=f2ca158502a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2ca158502a0, replyNumber=0, likeNumber=36, createdTime=2019-01-22, rootId=0, userName=zhyy89, userId=776d2903072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2ca158502a0, moduleTitle=Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2ca158502a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

BMC Urol：晚期前列腺癌患者服用阿帕鲁胺后出现皮疹，需要特殊处理吗？

2021-08-07

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

European Urology：热门靶点CD38在晚期前列腺癌中的作用

2021-06-13

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

Clin Cancer Res：对3334名晚期前列腺癌患者的循环肿瘤DNA进行基因组学分析确定了可靶向的BRCA变异和AR耐药机制

2021-03-01

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

J Clin Oncol：全盆腔预防性放疗较单纯前列腺放疗可进一步改善局部晚期前列腺癌患者预后

2021-02-03

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

FDA批准口服GnRH受体拮抗剂Orgovyx治疗晚期前列腺癌

2020-12-22

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

Eur Urol：ATM缺失的晚期前列腺癌：PARP和ATR抑制剂

2020-12-15

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月

2020-10-17

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

Brit J Cancer：晚期前列腺癌中富集的BCAS2蛋白能够与NBS1互作增强DNA双链断裂修复

2020-10-08

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

Communications Biology：晚期前列腺癌帐长非编码RNAs与雄激素受体剪接因子相关

2020-08-12

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

Nat Genet：晚期前列腺癌的DNA甲基化情况

2020-08-05

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

J Urol：GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率

2020-07-14

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

NEJM：口服Relugolix治疗晚期前列腺癌

2020-06-06

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

美国FDA批准RV001治疗晚期前列腺癌的IIb期临床试验

2020-03-03

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

2019 APCCC报告：晚期前列腺癌患者的管理

2020-02-20

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

叶定伟：晚期前列腺癌治疗进展盘点

2020-01-07

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%

2019-12-06

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期

2019-12-04

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

晚期前列腺癌新药研发竞争格局

2019-10-24

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

新型晚期前列腺癌靶向诊疗技术在英国首次上市

2019-06-06

zhyy89 (审核中...)

前往app查看评论内容

#晚期前列腺癌#

Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体

2019-01-22

科室
- - 订阅+
  - 更多科室
工具
服务